[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-453491-105":59,"doc-detail-453491-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","predictors-of-response-to-imatinib-therapy-and-long-term-outcomes-in-paediatric-and-adolescent-patients-with-chronic-myeloid-leukaemia","Predictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia","","Chronic myeloid leukaemia (CML) in children is uncommon, and clinical applicability of risk scoring and prognostic predictors remains unclear. A retrospective study evaluated 104 paediatric patients (≤18 years) with CML chronic phase treated between 2007 and 2024, recording baseline characteristics, RT-PCR molecular transcripts, response milestones, computed risk scores, and long-term survival outcomes. Results showed high early haematological response and defined molecular response rates, with specific associations to MMR achievement and survival endpoints.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/predictors-of-response-to-imatinib-therapy-and-long-term-outcomes-in-paediatric-and-adolescent-patients-with-chronic-myeloid-leukaemia/453491/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/predictors-of-response-to-imatinib-therapy-and-long-term-outcomes-in-paediatric-and-adolescent-patients-with-chronic-myeloid-leukaemia/453491.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient group and study period were analyzed?","Question",{"text":112,"@type":113},"The study retrospectively analyzed 104 newly diagnosed paediatric patients with CML chronic phase, aged ≤18 years, treated at a single centre between 2007 and 2024.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were response outcomes assessed in the study?",{"text":117,"@type":113},"Haematological response, molecular response, and long-term survival were collected from medical records, with molecular transcripts measured by RT-PCR and risk scores correlated with clinical outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were linked to achieving major molecular response (MMR)?",{"text":121,"@type":113},"Sokal scoring system and EMR at 3 months were significantly correlated with achieving MMR at 12 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},453491,1790948094,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Cancer Reports  \nORIGINAL ARTICLE  OPEN ACCESS   \nPredictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia  \nSouvik Saha  | Sanjeev Yadav | Manish Kumar Singh  | Khaliqur Rahman  | Dinesh Chandra | Ruchi Gupta | Rajesh Kashyap   \nDepartment of Hematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India Correspondence: Rajesh Kashyap ([rajkashyapmd@gmail.com](rajkashyapmd@gmail.com))  \nReceived: 18 July 2025 | Revised: 26 November 2025 | Accepted: 9 December 2025  \nKeywords: chronic myeloid leukaemia | imatinib | India | paediatric  \nABSTRACT  \nBackground: Chronic myeloid leukaemia (CML) is an infrequent myeloproliferative neoplasm in the paediatric population as compared to adults. Despite vast progress in understanding the disease biology and therapy of CML-chronic phase (CML CP), the applicability of risk scoring systems in practice and prognostic factors in children remain grey areas. Hence, we tried to analyse disease characteristics, molecular response to frontline imatinib therapy and its clinical predictors along with long-term outcomes in our population.  \nMaterials and Methods: In this study, we retrospectively analysed 104 paediatric patients aged ≤18years, diagnosed with CML CP, treated at our centre between 2007 and 2024. Their baseline demographic profile, clinical characteristics, haematological parameters and molecular transcripts as diagnosed by RT-PCR were recorded. The follow-up response assessments, including haematological response, molecular response and long-term survival, were collected from medical records. Risk scores were computed and correlated with clinical outcomes.  \nResults: Our study included 104 paediatric patients presenting with CML CP. Splenomegaly was a universal feature with a median size of 10 cm below costal margin. The majority of patients belonged to the low-risk group according to Sokal, EUTOS and ELTS systems. Imatinib was initiated in all of them and was followed up for a median duration of 72 months. Overall, 95.2% patients achieved complete hematologic response (CHR) at 3 months. A total of 42.5%(43/101) patients achieved MMR at 12 months and 54.4%(55/101) patients achieved MMR at 18 months. Sokal scoring system and EMR at 3 months were significantly correlated with the achievement of MMR at 12 months. A total of 11 patients progressed to blast crisis and 10 patients expired in due course of the disease. The 2-and 10-year PFS was 96% and 82%, respectively. CHR at 3 months was significantly predictive of PFS. None of the scoring systems had predictive value for PFS.  \nConclusion: This is one of the largest reported data on Indian paediatric CML CP patients with long-term outcomes. The dynamics of adult CML, including risk scores, do not perfectly fit the scenario of paediatric patients. Hence, further studies and newer strategies are required for optimal management of paediatric CML patients.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Cancer Reports published by Wiley Periodicals LLC.  \nCancer Reports, 2026; 9:e70430 1 of 10  \n[https://doi.org/10.1002/cnr2.70430](https://doi.org/10.1002/cnr2.70430)  \n1 | Introduction  \nChronic myeloid leukaemia (CML) is amyeloproliferative disease associated with the presence of Philadelphia (Ph) chromosome which results from a reciprocal chromosomal translocation, t(9; 22) (q34; q11), which leads to the formation of constitutively expressing BCR::ABL tyrosine kinase fusion protein [1] . CML in the paediatric population is rare. According to SEER data, CML accounts for only 2% of all paediatric leukaemias below 15 years [2] . There is a scarcity of data on the incidence of paediatric CML in India. Children and adolescents have a more aggressive presentation when com","cbCail02W2HaKwTi","https://ap.wps.com/l/cbCail02W2HaKwTi","pdf",528007,"English","# Introduction\n# Materials and Methods\n## Study Population","[{\"question\":\"What patient group and study period were analyzed?\",\"answer\":\"The study retrospectively analyzed 104 newly diagnosed paediatric patients with CML chronic phase, aged ≤18 years, treated at a single centre between 2007 and 2024.\"},{\"question\":\"How were response outcomes assessed in the study?\",\"answer\":\"Haematological response, molecular response, and long-term survival were collected from medical records, with molecular transcripts measured by RT-PCR and risk scores correlated with clinical outcomes.\"},{\"question\":\"Which factors were linked to achieving major molecular response (MMR)?\",\"answer\":\"Sokal scoring system and EMR at 3 months were significantly correlated with achieving MMR at 12 months.\"}]","Predictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia | PDF",1790738968,25]